Pyxis Oncology Files Definitive Proxy Statement

TL;DR

Pyxis Oncology's proxy statement is out - time to vote on board members and auditors.

AI Summary

Pyxis Oncology, Inc. filed its definitive proxy statement on April 29, 2025, for its annual meeting. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key details regarding director nominations and the appointment of its independent registered public accounting firm are expected to be presented.

Why It Matters

This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction at the upcoming annual meeting.

Risk Assessment

Risk Level: low — This is a routine filing for a proxy statement, providing information for an upcoming shareholder meeting.

Key Players & Entities

• Pyxis Oncology, Inc. (company) — Registrant
• 0000950170-25-059573 (filing_id) — Accession Number
• 20250429 (date) — Filing Date

FAQ

From the Filing

0000950170-25-059573.txt : 20250429 0000950170-25-059573.hdr.sgml : 20250429 20250429074102 ACCESSION NUMBER: 0000950170-25-059573 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 8 CONFORMED PERIOD OF REPORT: 20250429 FILED AS OF DATE: 20250429 DATE AS OF CHANGE: 20250429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pyxis Oncology, Inc. CENTRAL INDEX KEY: 0001782223 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 831160910 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40881 FILM NUMBER: 25882701 BUSINESS ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 BUSINESS PHONE: (617) 221-9059 MAIL ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 DEF 14A 1 2025_pyxs-14a.htm DEF 14A DEF 14A   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ ​ ​ Filed by a Party other than the Registrant    ☐ Check the appropriate box: 5  ☐ ​ ​ Preliminary Proxy Statement   ☐ ​ ​ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ ​ ​ Definitive Proxy Statement   ☐ ​ ​ Definitive Additional Materials   ☐ ​ ​ Soliciting Material under § 240.14a-12   PYXIS ONCOLOGY, INC. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ ​ ​ No fee required.   ☐ ​ ​ Fee paid previously with preliminary materials.   ☐ ​ ​ Fee computed on table in exhibit required per Exchange Act Rules 14a-6(i)(1) and 0-11.           PYXIS ONCOLOGY, INC. 321 Harrison Avenue Boston, Massachusetts 02118 NOTICE OF THE 2025 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD JUNE 18, 2025   DEAR STOCKHOLDERS: NOTICE IS HEREBY GIVEN that the 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Pyxis Oncology, Inc., a Delaware corporation, will be held on June 18, 2025, at 09:00 a.m. Eastern Standard Time in a virtual meeting format only. We believe hosting a virtual meeting enables participation by more of our stockholders, while lowering the cost of conducting the meeting. Stockholders attending the virtual meeting will be afforded the same rights and opportunities to participate as they would at an in-person meeting. We encourage you to attend online and participate. In order to attend the Annual Meeting, you must register at www.proxydocs.com/PYXS . Upon completing your registration, you will receive further instructions via email, including a unique link that will allow you access to the Annual Meeting and to vote and submit questions during the Annual Meeting. We recommend that you log in a few minutes before 09:00 a.m., Eastern Standard Time, on June 18, 2025 to ensure you are logged in when the Annual Meeting begins. During the Annual Meeting, stockholders will be asked to consider the following matters, as more fully described in the proxy statement accompanying this notice: 1. the election of three Class I directors named in the proxy statement; 2. the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and 3. the transaction of such other business as may properly come before the meeting, or any adjournment or postponement thereof. These items of business are more fully described in the proxy statement accompanying this notice.